Latest News Feed
Note purchase targeted to close by December 31, 2026; roadmap update on OSRK reverse takeover discussions, OTCQB uplisting and VXM01 manuscript
Potential reverse takeover is a key pillar of plan to return portfolio to a national exchange; OSR Health also pursuing OTCQB uplisting
Company evaluating options to regain compliance; further update expected by November 6, 2026; $15 million VXM01 funding mechanism remains in place; committed to continuing Shareholder Loyalty Program
The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline
Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program.
Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development
Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months
Read the CEO’s letter outlining OSR Health’s proposed Shareholder Loyalty CVR Program, VXM01 progress, Woori IO and the company’s long-term strategy
Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones
OSR Holdings is now OSR Health, reflecting its mission to advance healthcare innovation across biotechnology, medical technology and wellness markets.
OSR Holdings CEO update on Nasdaq compliance, strategic biotech portfolio progress, and long-term value creation across subsidiaries in 2026
Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders
OSR Holdings (NASDAQ: OSRH) eliminates $2M warrant overhang via a $1.00 fixed-price convertible note with six-month conversion restriction.